Logotype for US Physical Therapy Inc

US Physical Therapy (USPH) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for US Physical Therapy Inc

Q1 2026 earnings summary

13 May, 2026

Executive summary

  • Q1 2026 net revenue grew 7.9% year-over-year to $198.3 million, driven by both physical therapy and industrial injury prevention segments.

  • Net income attributable to shareholders was $5.0 million, down from $9.9 million in Q1 2025, impacted by a $2.0 million loss on contingent earn-out revaluation and higher corporate costs.

  • Adjusted EBITDA rose to $20.2 million from $19.5 million year-over-year.

  • Patient volume increased 6.9% year-over-year, with daily visits per clinic rising to 31.8.

  • Strategic initiatives include front desk virtualization, AI-assisted documentation, remote monitoring, and expansion of hospital alliances.

Financial highlights

  • Physical therapy net revenue was $167.7 million, up 7.2% year-over-year; industrial injury prevention revenue was $30.6 million, up 11.8%.

  • Net patient revenue per visit increased to $106.49.

  • Adjusted EBITDA margin was 13.1% in Q1 2026 versus 13.7% in Q1 2025.

  • Gross profit increased 5.4% to $32.8 million, but gross margin declined to 16.5% from 16.9% year-over-year.

  • Earnings per share was a loss of $0.12, compared to earnings of $0.80 in Q1 2025, due to non-cash adjustments for redeemable non-controlling interests.

Outlook and guidance

  • Full-year 2026 adjusted EBITDA guidance reaffirmed at $102–$106 million.

  • Guidance includes partial year impact of two new hospital affiliations and Medicare rate increase.

  • Hospital alliances expected to add at least $7.3 million in annualized EBITDA upon full integration.

  • Management expects continued growth through acquisitions and new clinic development.

  • Additional acquisitions and hospital alliances not yet included in guidance could provide further upside.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more